Primary immune thrombocytopenia (ITP) is a common autoimmune disease in which refractory ITP places a heavy burden on patients and society. The purpose of this article is to analyze the prevalence and burden of refractory primary immune thrombocytopenia and analyze the relevant influencing factors. Through literature review and data analysis, we found that prevalence varies across regions and populations, while the burden is mainly reflected in healthcare costs, reduced work capacity and psychosocial stress. Factors such as age, gender, disease severity, and healthcare resources also influence prevalence and burden. With the advancement of medical technology, new methods such as immunity and regenerative medicine have brought hope to patients. Future research should focus on reducing medical costs and improving the best outcomes to reduce the burden on patients and society.
Keywords: Primary immune thrombocytopenia; prevalence; Burden; influencing factors; **Method.
1. Background.
Primary immune thrombocytopenia (ITP) is a common autoimmune disease, in which refractory ITP has a high prevalence and burden. Patients with ITP have a decreased platelet count, leading to an increased risk of bleeding and affecting the patient's quality of life. Refractory ITP refers to ITP that does not respond well to routine ** or cannot be tolerated, which is difficult and has a poor quality of life for patients. Therefore, understanding the prevalence and burden of refractory primary immune thrombocytopenia is of great significance for improving the quality of life and social burden of patients.
2. Research Methodology.
This study used literature review and data analysis to study the prevalence and burden of **refractory primary immune thrombocytopenia. By searching relevant databases and academic journals, relevant research data at home and abroad were collected, and the data were collated and analyzed.
3. Prevalence assessment.
Based on study data across regions and populations, there are differences in the prevalence of refractory primary immune thrombocytopenia. Overall, the prevalence increases with age, with slightly more women than men. In addition, there are differences in prevalence between diagnostic groups and disease severity.
4. Burden analysis.
*Refractory primary immune thrombocytopenia places a heavy burden on patients and society. The burden is mainly reflected in medical costs, reduced work capacity and psychosocial stress. Patients require long-term** and management, resulting in higher medical costs. At the same time, the disease has a negative impact on the patient's ability to work and social participation, leading to a decrease in productivity and an increase in social burden. In addition, the psychological and emotional stress of the patient also takes a toll on the family and society.
5. Influencing factors**.
Factors such as age, sex, disease severity, and healthcare resources influence the prevalence and burden of refractory primary immune thrombocytopenia. The prevalence is higher in older patients and women, and disease severity is positively correlated with prevalence. The unequal availability and distribution of health resources is also an important factor affecting prevalence and burden. In addition, regional, economic, and cultural differences have an impact on prevalence and burden.
6. Future trends and development directions.
With the advancement of medical science and technology, some new progress has been made in the diagnosis and development of primary immune thrombocytopenia. For example, the advent of new immunology and regenerative medicine methods has given patients more options. At the same time, through the application of precision medicine and individualized strategies, the best results can be improved and medical costs can be reduced. Future research should focus on reducing medical costs and improving the best outcomes to reduce the burden on patients and society. In addition, strengthening international cooperation and multidisciplinary integration** is also the way forward.
VII. Conclusions. **Refractory primary immune thrombocytopenia has a high prevalence and burden, negatively impacting patients' quality of life and family social burden. Therefore, it is necessary to further strengthen the research on its prevention and ** to improve the quality of life of patients and reduce the social burden. At the same time, relevant influencing factors such as age, gender, disease severity, and medical resources should be paid attention to, and effective interventions should be taken to reduce risk and improve prognosis. Future research should be combined with the current development trend of medical science and technology to explore new methods and management models to better serve clinical practice and patient needs.